Home | Contact Us | Log In
(888) 789-6604
Report Stack
Advanced search
Account Detail 0 items in basket
Order History Total $
Saved Searches View Basket basket
Nasopharyngeal Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Publication Date Apr 2012
Publisher GlobalData
Product Type Report
Pages 74
Single User License $ 3995.00
Site User License $ 7990.00
Corporate User License $ 11985.00
 

Reportstack.com does not charge credit card fee, transaction charges, extra tax or VAT on any purchase.

Nasopharyngeal Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, “Nasopharyngeal Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global nasopharyngeal cancer therapeutics market. The report identifies the key trends shaping and driving the global nasopharyngeal cancer therapeutics market. It also provides insights into the current competitive landscape and the emerging players expected to significantly alter the market positions of the current market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global nasopharyngeal cancer therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimates that the global (the seven key markets of the US, the UK, Germany, Italy, France, Spain and Japan) nasopharyngeal cancer therapeutics market was valued at $53.0m in 2011 and forecasts it to grow at a Compound Annual Growth Rate (CAGR) of 0.5% to reach $55.0m by 2019. The existing market is strong, and is represented by three approved products – Erbitux (cetuximab), Taxotere (docetaxel) and Blenoxane (bleomycin), of which only the former is patent protected. Erbitux is currently approved in the US and European Union (EU) but not in Japan. The growth during 2006-2011 is primarily attributed to launch of Taxotere and Erbitux for the treatment of Squamous Cell Carcinoma of the Head and Neck (SCCHN). Although there are no molecules in the late stage of clinical development and there is an expected patent expiry of the targeted therapy drug Erbitux, the slow growth rate during the forecast period is due to the slow increase in the prevalence of nasopharyngeal cancer, which has led to an increase in the drug-treated population.

Scope

The report provides information on the key drivers and challenges of the nasopharyngeal cancer market. Its scope includes -
- Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) nasopharyngeal cancer market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing analysis of the different Phases of development, mechanisms of action and emerging trends. Pipeline candidates for nasopharyngeal cancer fall under the following therapeutic classes: Vascular Endothelial Growth Factor (VEGF) inhibitors, Immunotherapeutic agents, cell factor receptor (c-Kit) inhibitors, VEGF and platelet-derived growth factor (PDGFR) inhibitors, Allosteric Akt inhibitor, cyclin-dependent kinase (CDK) inhibitor, Thymidylate synthase inhibitors, Toll-Like Receptor 8 (TLR8) agonists, and (Mammalian Target of Rapamycin) mTOR inhibitors.
- Analysis of the current and future competition in the global nasopharyngeal cancer market is provided. The key market players are Cyclacel Pharmaceuticals and F. Hoffman-LaRoche.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the nasopharyngeal cancer therapeutics market.
- Analysis of key recent licensing and partnership agreements in the nasopharyngeal cancer therapeutics market.

Reasons to buy

The report will enhance your decision-making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global nasopharyngeal cancer market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global nasopharyngeal cancer market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global nasopharyngeal cancer market landscape? – Identify, understand and capitalize.


Companies Mentioned

Cyclacel Pharmaceuticals Inc. F. Hoffmann-La Roche Ltd.

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Nasopharyngeal Cancer Therapeutics - Introduction 7
2.1 Overview 7
2.2 Epidemiology 8
2.3 Etiology and Risk Factors 9
2.4 Signs and Symptoms 9
2.5 Diagnosis 10
2.6 Staging (TNM Classification) 11
2.7 Treatment 17
2.7.1 Radiation Therapy 17
2.7.2 Chemotherapy 18
2.7.3 Surgery 19
2.7.4 Treatment by Stage of Disease 19
2.8 Nasopharyngeal Cancer in China 20
2.9 GlobalData Pipeline Report Guidance 21
3 Nasopharyngeal Cancer Therapeutics - Market Characterization 22
3.1 Nasopharyngeal Cancer Therapeutics Market Size (2006-2011) – Global 22
3.2 Nasopharyngeal Cancer Therapeutics Market Forecast (2011-2019) – Global 24
3.3 Nasopharyngeal Cancer Therapeutics Market Size (2006-2011) – The US 26
3.4 Nasopharyngeal Cancer Therapeutics Market Forecast (2011-2019) – The US 27
3.5 Nasopharyngeal Cancer Therapeutics Market Size (2006-2011) – The UK 28
3.6 Nasopharyngeal Cancer Therapeutics Market Forecast (2011-2019) – The UK 29
3.7 Nasopharyngeal Cancer Therapeutics Market Size (2006-2011) – France 30
3.8 Nasopharyngeal Cancer Therapeutics Market Forecast (2011-2019) – France 31
3.9 Nasopharyngeal Cancer Therapeutics Market Size (2006-2011) – Germany 32
3.10 Nasopharyngeal Cancer Therapeutics Market Forecast (2011-2019) – Germany 33
3.11 Nasopharyngeal Cancer Therapeutics Market Size (2006-2011) – Italy 34
3.12 Nasopharyngeal Cancer Therapeutics Market Forecast (2011-2019) – Italy 35
3.13 Nasopharyngeal Cancer Therapeutics Market Size (2006-2011) – Spain 36
3.14 Nasopharyngeal Cancer Therapeutics Market Forecast (2011-2019) – Spain 37
3.15 Nasopharyngeal Cancer Therapeutics Market Size (2006-2011) – Japan 38
3.16 Nasopharyngeal Cancer Therapeutics Market Forecast (2011-2019) – Japan 39
3.17 Drivers and Barriers for the Nasopharyngeal Cancer Therapeutic Market 40
3.17.1 Drivers for the Nasopharyngeal Cancer Therapeutics Market 40
3.17.2 Barriers for the Nasopharyngeal Cancer Therapeutics Market 40
3.18 Key Events Impacting the Future Market 41
3.19 Opportunity and Unmet Need 41
3.20 Key Takeaway 42
4 Nasopharyngeal Cancer Therapeutics Market - Competitive Assessment 43
4.1 Overview 43
4.1.1 Strategic Competitor Assessment 43
4.2 Nasopharyngeal Cancer Market Marketed products profile 45
4.2.1 Erbitux (cetuximab) 45
4.2.2 Taxotere (docetaxel) 46
4.2.3 Blenoxane (bleomycin sulfate) 48
4.3 Key Takeaway 49
5 Nasopharyngeal Cancer Therapeutics Market - Pipeline Assessment 50
5.1 Overview 50
5.2 Strategic Pipeline Assessment 50
5.3 Nasopharyngeal Cancer Pipeline Analysis – Pipeline by Clinical Phases of Development 50
5.3.1 Nasopharyngeal Cancer Therapeutics – Phase II Clinical Pipeline 51
5.3.2 Nasopharyngeal Cancer Therapeutics – Phase I Clinical Pipeline 51
5.4 Nasopharyngeal Cancer Pipeline by Mechanism of Action 52
5.5 Nasopharyngeal Cancer Technology Trends Analytical Framework 53
5.6 Nasopharyngeal Cancer Therapeutics – Promising Drugs under Clinical Development 54
5.7 Profiles of Selected Late Stage Drugs under Clinical Development 54
5.7.1 Seliciclib (CYC202) 54
5.7.2 Xeloda (capecitabine) 55
5.8 Key Takeaway 55
6 Nasopharyngeal Cancer Therapeutics - Clinical Trials Mapping 56
6.1 Clinical Trials Mapping by Country (The US, EU5 and Japan) 56
6.2 Clinical Trials Mapping by Phase 57
6.3 Clinical Trials Mapping by Trial Status 58
6.4 Clinical Trials Mapping by Overall Sponsors 59
6.5 Clinical Trial Mapping by Prominent Sponsors 60
7 Nasopharyngeal Cancer Therapeutics - Strategic Assessment 61
7.1 Future Market Competition Scenario 61
8 Global Nasopharyngeal Cancer Therapeutics - Future Players in The Market 62
8.1 Introduction 62
8.2 Company Profiles 63
8.2.1 Cyclacel Pharmaceuticals Inc. 63
8.2.2 F. Hoffmann-La Roche Ltd. 63
9 Nasopharyngeal Cancer Therapeutics - Appendix 67
9.1 Acronyms 67
9.2 Research Methodology 69
9.2.1 Coverage 69
9.2.2 Secondary Research 69
9.2.3 Forecasting 70
9.2.4 Primary Research 72
9.2.5 Expert Panel Validation 72
9.3 Contact Us 72
9.4 Disclaimer 72
9.5 Bibliography 73

List of Tables
1.1 List of Tables
Table 1: Nasopharyngeal Cancer, Incidence and Mortality by Country, 2011 8
Table 2: Nasopharyngeal Cancer - TNM Definitions 11
Table 3: Nasopharyngeal Cancer Staging and Treatment options Based on Stage of Disease 12
Table 4: Nasopharyngeal Cancer – Chemotherapy Regimens for Locally Advanced Stage (Stage II-IVB) 18
Table 5: Nasopharyngeal Cancer – First-Line Chemotherapy Regimens for Metastatic or Recurrent Stage (Stage IVC) 18
Table 6: Nasopharyngeal Cancer - Second and Third Line Chemotherapy Regimens for Metastatic or Recurrent Stage (Stage IVC) 19
Table 7: Nasopharyngeal Cancer Therapeutics, Global, Market Revenue, $m), 2006-2011 22
Table 8: Nasopharyngeal Cancer Therapeutics, Global, Revenue Forecasts ($m), 2011-2019 24
Table 9: Nasopharyngeal Cancer Therapeutics, the US, Market Historical Revenue ($m), 2006-2011 26
Table 10: Nasopharyngeal Cancer Therapeutics, the US, Revenue Forecasts ($m), 2011-2019 27
Table 11: Nasopharyngeal Cancer Therapeutics, the UK, Market Historical Revenue ($m), 2006-2011 28
Table 12: Nasopharyngeal Cancer Therapeutics, the UK, Revenue Forecasts ($m), 2011-2019 29
Table 13: Nasopharyngeal Cancer Therapeutics, France, Market Historical Revenue ($m), 2006-2011 30
Table 14: Nasopharyngeal Cancer Therapeutics, France, Revenue Forecasts ($m), 2011-2019 31
Table 15: Nasopharyngeal Cancer Therapeutics, Germany, Market Historical Revenue ($m), 2006-2011 32
Table 16: Nasopharyngeal Cancer Therapeutics, Germany, Revenue Forecasts ($m), 2011-2019 33
Table 17: Nasopharyngeal Cancer Therapeutics, Italy, Market Historical Revenue ($m), 2006-2011 34
Table 18: Nasopharyngeal Cancer Therapeutics, Italy, Revenue Forecasts ($m), 2011-2019 35
Table 19: Nasopharyngeal Cancer Therapeutics, Spain, Market Historical Revenue ($m), 2006-2011 36
Table 20: Nasopharyngeal Cancer Therapeutics, Spain, Revenue Forecasts ($m), 2011-2019 37
Table 21: Nasopharyngeal Cancer Therapeutics, Japan, Market Historical Revenue ($m), 2006-2011 38
Table 22: Nasopharyngeal Cancer Therapeutics, Japan, Revenue Forecasts ($m), 2011-2019 39
Table 23: Nasopharyngeal Cancer Therapeutics – Phase II Clinical Pipeline, 2011 51
Table 24: Nasopharyngeal Cancer Therapeutics – Phase I Clinical Pipeline, 2011 51
Table 25: Nasopharyngeal Cancer Therapeutics – Promising Drugs Under Clinical Development, 2011 54
Table 26: Nasopharyngeal Cancer Therapeutics – Clinical Trials by Country, 2011 56
Table 27: Nasopharyngeal Cancer Therapeutics – Clinical Trials by Phase, 2011 57
Table 28: Nasopharyngeal Cancer Therapeutics – Clinical Trials by Status, 2011 58
Table 29: Nasopharyngeal Cancer Therapeutics – Clinical Trials by Overall Sponsors, 2011 59
Table 30: Nasopharyngeal Cancer Therapeutics – Clinical trials by Prominent Sponsors, 2011 60
Table 31: Cyclacel Pharmaceuticals Inc. – Promising Molecules in Pipeline for Nasopharyngeal Cancer, 2011 63
Table 32: F. Hoffmann-La Roche Ltd. – Promising Molecules in Pipeline for Nasopharyngeal Cancer, 2011 66

List of Figures
1.2 List of Figures
Figure 1: Anatomy of Nasopharynx 7
Figure 2: Nasopharyngeal Cancer – Stage 0 13
Figure 3: Nasopharyngeal Cancer – Stage I 13
Figure 4: Nasopharyngeal Cancer – Stage IIA (T2, N0, M0) 14
Figure 5: Nasopharyngeal Cancer – Stage IIB (T1 or T2, N1, M0) 14
Figure 6: Nasopharyngeal Cancer – Stage III 15
Figure 7: Nasopharyngeal Cancer – Stage IVA 15
Figure 8: Nasopharyngeal Cancer – Stage IVB 16
Figure 9: Nasopharyngeal Cancer – Stage IVC 16
Figure 10: Nasopharyngeal Cancer Therapeutics, Global, Market Revenue ($m), 2006-2011 22
Figure 11: Nasopharyngeal Cancer Therapeutics, Market Share ($m, %), 2011 23
Figure 12: Nasopharyngeal Cancer Therapeutics, Global, Revenue Forecasts ($m), 2011-2019 24
Figure 13: Nasopharyngeal Cancer Therapeutics, Forecasted Market Share ($m, %), 2019 25
Figure 14: Nasopharyngeal Cancer Therapeutics, the US, Market Historical Revenue ($m), 2006-2011 26
Figure 15: Nasopharyngeal Cancer Therapeutics, the US, Revenue Forecasts ($m), 2011-2019 27
Figure 16: Nasopharyngeal Cancer Therapeutics, the UK, Market Historical Revenue ($m), 2006-2011 28
Figure 17: Nasopharyngeal Cancer Therapeutics, the UK, Revenue Forecasts ($m), 2011-2019 29
Figure 18: Nasopharyngeal Cancer, France, Market Historical Revenue ($m), 2006-2011 30
Figure 19: Nasopharyngeal Cancer Therapeutics, France, Revenue Forecasts ($m), 2011-2019 31
Figure 20: Nasopharyngeal Cancer Therapeutics, Germany, Market Historical Revenue ($m), 2006-2011 32
Figure 21: Nasopharyngeal Cancer Therapeutics, Germany, Revenue Forecasts ($m), 2011-2019 33
Figure 22: Nasopharyngeal Cancer Therapeutics, Italy, Market Historical Revenue ($m), 2006-2011 34
Figure 23: Nasopharyngeal Cancer Therapeutics, Italy, Revenue Forecasts ($m), 2011-2019 35
Figure 24: Nasopharyngeal Cancer Therapeutics, Spain, Market Historical Revenue ($m), 2006-2011 36
Figure 25: Nasopharyngeal Cancer Therapeutics, Spain, Revenue Forecasts ($m), 2011-2019 37
Figure 26: Nasopharyngeal Cancer Therapeutics, Japan, Market Historical Revenue ($m), 2006-2011 38
Figure 27: Nasopharyngeal Cancer Therapeutics, Japan, Revenue Forecasts ($m), 2011-2019 39
Figure 28: Nasopharyngeal Cancer Therapeutics, Key Events Impacting Future Market, 2011 41
Figure 29: Opportunity and Unmet Need in the Nasopharyngeal Cancer Therapeutic Market, 2011 42
Figure 30: Nasopharyngeal Cancer Therapeutics Market – Strategic Competitor Assessment, 2011 44
Figure 31: Nasopharyngeal Cancer Therapeutics Pipeline by Phase of Clinical Development, 2011 50
Figure 32: Nasopharyngeal Cancer Market – Clinical Pipeline by Mechanism of Action, 2011 52
Figure 33: Technology Trends Analytical Framework of the Nasopharyngeal Cancer Pipeline, 2011 53
Figure 34: Technology Trends Analytical Framework of the Nasopharyngeal Cancer Pipeline – Description, 2011 53
Figure 35: Nasopharyngeal Cancer Therapeutics – Clinical Trials by Country, 2011 56
Figure 36: Nasopharyngeal Cancer Therapeutics – Clinical Trials by Phase, 2011 57
Figure 37: Nasopharyngeal Cancer Therapeutics – Clinical Trials by Status, 2011 58
Figure 38: Nasopharyngeal Cancer Therapeutics – Clinical Trials by Overall Sponsors, 2011 59
Figure 39: Nasopharyngeal Cancer Therapeutics – Clinical Trials by Prominent Sponsors, 2011 60
Figure 40: Nasopharyngeal Cancer Therapeutics, Strategic Assessment, 2011 61
Figure 41: Nasopharyngeal Cancer Therapeutics, Clinical Pipeline by Company, 2011 62
Figure 42: GlobalData market Forecasting Model, 2011 71

Title Date Price
By Netscribes (India) Pvt. Ltd.
May 2012 $0.00
Medical Devices Market in Russia 2009-2013
By Infiniti Research Ltd
Medical devices comprise surgical equipment & appliances, diagnostic devices, X-ray, ophthalmic equipment, laboratory devices & diagnostics, dental equipment, medical disposables and others.The Russia ...Read More
Mar 2010 $1500.00
2010 Perfect Vision GmbH - Medical Equipment - Deals and Alliances Profile
By GlobalData
2010 Perfect Vision GmbH - Medical Equipment - Deals and Alliances ProfileSummary20/10 Perfect Vision AG is engaged in the development, manufacturing and marketing of innovative technologies for raisi ...Read More
Jan 2012 $250.00
2010 U.S. Ambulatory Surgical & Emergency Centers Industry Report
By Barnes Reports
The U.S Ambulatory Surgical & Emergency Centers Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features ...Read More
Jan 2010 $149.00
2010 U.S. Biological Product Manufacturing Industry Report
By Barnes Reports
The U.S. Biological Product Manufacturing Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2010 ...Read More
Jan 2010 $149.00
2010 U.S. HMO Medical Centers Industry Report
By Barnes Reports
The U.S HMO Medical Centers Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2010 current and 20 ...Read More
Jan 2010 $149.00
2010 U.S. Home Health Care Services Industry Report
By Barnes Reports
The Home Health Care Services Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2010 current and ...Read More
Oct 2009 $149.00
2010 U.S. Kidney Dialysis Centers Industry Report
By Barnes Reports
The U.S Kidney Dialysis Centers Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2010 current an ...Read More
Jan 2010 $149.00
2010 U.S. Medical & Surgical Hospitals Industry Report
By Barnes Reports
The Medical & Surgical Hospitals Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2010 current a ...Read More
Oct 2009 $149.00
2010 U.S. Medical Laboratories Industry Report
By Barnes Reports
The Medical Laboratories Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2010 current and 2011 ...Read More
Oct 2009 $149.00

  * Required field
Name *
E-mail *
Telephone 
Company *
Country *
Query 
 
   

   
For support please
contact:
US Toll Free
+1 888-789-6604
Asia Pacific
+91-9425069161
 
 
To receive alerts about
an update, future offers and discounts on this report, signup here.
Email ID
 

Companies


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Countries


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z